SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff and repeated tests of recent lows have traders focused on its heavy debt, financing costs and ability to fund AI infrastructure growth. Bears warn of dilution or financial distress, while bulls point to AI demand and contracted backlog and treat the weakness as a buying opportunity; Goldmans upgrade and ARKs purchases have not ended the debate.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is under pressure amid a broader semiconductor selloff and concerns about AI spending, financing, and the sustainability of the trade; CEO Hock Tans remarks comparing some AI investing to gambling have become a flashpoint for traders. The community is split between viewing the decline as sector-wide weakness and a buying opportunity, and seeing persistent underperformance as a sign of deeper valuation or demand risks.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a prolonged post-IPO selloff, with traders citing lockup expirations and insider-share supply, a TD Cowen price-target cut, and concerns about OpenAI customer concentration, scaling, and Nvidia competition. Bears see continued selling pressure, while bulls argue the decline is overdone and point to Cerebras AI-chip technology and backlog.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding alongside semiconductor stocks after a steep, extended selloff, drawing dip buyers who see oversold conditions and continued AI-chip demand as support for a recovery. Others warn the bounce may be temporary, citing concerns about AI investment returns and debt, market uncertainty, and upcoming chip-sector earnings.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs volatile price action is being debated against concerns about token unlocks and dilution, which traders blame for persistent selling. Bulls point to Starknets quantum-resistant technology, Bitcoin integration, privacy features and possible shift to an independent Layer 1, while skeptics question whether those developments can overcome supply pressure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile AI and semiconductor rebound, as traders debate whether credit strains at AI infrastructure firms such as CoreWeave and uncertain returns on data-center spending could undermine chip demand. Dip buyers see continued AI demand and upcoming hyperscaler earnings and GTC commentary as reasons for confidence, while skeptics warn that the rally may fade.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention after a prolonged selloff and fresh lows, with traders debating whether high valuation, dilution and weak price action outweigh its defense-growth prospects. Bulls point to contract momentum and demand for drones and hypersonics as reasons the pullback may be an opportunity, while bears remain focused on the stocks continued decline.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention over concerns that its debt-funded AI data-center buildout and heavy capital spending could strain cash flow, amplified by widening credit-risk indicators and broader jitters around AI infrastructure financing. Traders are split between fears that spending and customer concentration pose serious risks and the view that Oracles cloud demand and backlog can eventually justify the investment, with some buying the selloff.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Scott Kirbys comments supporting a near-total inheritance tax have drawn sharp criticism, with some traders calling for a boycott of United. The discussion also focuses on the quarterly earnings report and recent share weakness, with traders divided between bearish concerns and potential upside if results and guidance reassure investors.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

SE is drawing attention for a sharp pullback despite strong Q2 growth; traders blame insider share sales and technical weakness, while bulls argue the sales were planned and point to Shopee and Monee growth as reasons to buy the dip.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oversold Conditions For Dyne Therapeutics (DYN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

Equity

RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial. 

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.read more...

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.


SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.


DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>RBC Capital cut its target to $30 from $35 while keeping an ‘Outperform’ rating, according to The Fly.</li><li>Dyne is developing Z-Basivarsen for myotonic dystrophy type 1.</li><li>On Tuesday, Novartis said its Phase 3 study of Del-Desiran failed to achieve its primary goal in patients with myotonic dystrophy type 1.</li></ul>Shares of Dyne Therapeutics (DYN) extended their sell-off on Wednesday, as Wall Street weighed the risk to its experimental muscle-disease drug following a major Phase 3 setback for Novartis (NVS).At the time of writing, <a href="https://stocktwits.com/symbol/DYN">DYN shares</a> traded 4.2% lower, having crashed more than 16% in the previous session.<h2 class="st-heading-2">Why DYN Stock Tanked</h2>On Tuesday, Novartis <a href="http://stocktwits.com/news-articles/markets/equity/nvs-stock-on-track-for-worst-day-in-over-20-years-after-second-trial-failure-in-a-week-dyn-srpt-slip-in-sympathy/cZtEeAyRJy2">said</a> its Phase 3 study of Del-Desiran failed to achieve its primary goal in patients with myotonic dystrophy type 1 (DM1). The rare genetic disease causes progressive muscle weakness and difficulty relaxing muscles after contraction, and currently has no approved treatment.Dyne is developing Z-Basivarsen for the same disease. Both companies’ studies use video hand opening time (vHOT), which measures how quickly a patient can open their hand after making a tight fist.Novartis’ drug failed to produce a statistically significant improvement on that measure, with Baird raising concerns about whether Dyne could face a similar problem.Dyne has enrolled 71 patients in the registrational expansion portion of its Phase 1/2 Achieve study for Z-Basivarsen. Topline results are expected in the first quarter of 2027.<h2 class="st-heading-2">Wall Street Remains Bullish</h2>Following Novartis’ trial data, Baird lowered its price target on Dyne to $26 from $30 but maintained an ‘Outperform’ rating, saying Novartis’ failure creates a challenging read-through for Dyne. The updated target still represents about 37% upside from current levels.RBC Capital also cut its target to $30 from $35 while keeping an ‘Outperform’ rating, but cautioned against directly applying Novartis’ results to Dyne. The firm pointed to differences in how the drugs target transferrin, their payloads, and their clinical trial designs, which it believes could lead to different outcomes.Morgan Stanley also said Novartis’ failure raises risk but believes Dyne's program still has potential. The brokerage lowered the target to $36 from $45 and maintained an ‘Overweight’ rating.The stock has a 12-month consensus price target of $37.53, while 16 of the 17 analysts covering the stock have rated it a ‘Buy’ and one ‘Sell,’ according to Koyfin.<h2 class="st-heading-2">Retail Says Go Long On DYN</h2>Despite the slump, retail sentiment surrounding DYN on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One user saw the slide in share price as a “long opportunity.”<stembedurl>https://stocktwits.com/CC_Abbott/message/663855724</stembedurl>DYN shares have gained around 5.5% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-stock-defies-market-selloff-after-compass-pathways-psilocybin-trial-success-pointing-to-2027-launch/cZt7EeeRJzj">CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of US biotech company Dyne Therapeutics Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Novartis AG

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$15.23
Prev Close	$14.25
Open	$14.45
Dividend Yield	0.00%
50-Day Moving Average	$20.31
Beta	1.94
Avg. Volume	3.62M
PE Ratio	-4.57

52-Week High	$27.31
52-Week Low	$14.00
Market Capitalization	$2.66B
EPS (Annual)	-$3.47
Price to Book	3.59
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DYN Fundamentals